New research in nuclear medicine and molecular imaging has led to breakthroughs in cancer diagnosis and treatment. Multispectral optoacoustic tomography detects blood flow problems before reconstructive surgery, while FAPI PET imaging assesses liver fibrosis in people with metabolic dysfunction–associated steatotic liver disease.
The partnership aims to strengthen quantitative molecular imaging by promoting harmonized approaches to image acquisition, reconstruction, and analysis. By developing and implementing shared standards, the organizations seek to improve the accuracy and consistency of quantitative imaging results.
Research in PSMA radioligand distribution reveals increased radiation exposure to healthy tissues. A new PET tracer detects kidney fibrosis, while EGFR-targeted radiotheranostics show promise against liver cancer. Clinical trials evaluate CXCR4-targeted therapy for acute leukemia and patient guidance for PSMA therapy.
A recent study published in The Journal of Nuclear Medicine found that local radiologists and nuclear medicine physicians can reliably interpret amyloid PET scans with high agreement, showing that visual reads performed in community settings are highly reliable for diagnosing and managing Alzheimer's disease. The study utilized data fr...
The TAME-Q software standardizes Tau PET image analysis, providing a transparent and reproducible workflow for neurodegenerative disease research. It successfully processed 133 datasets and correlated machine learning-derived tau scores with benchmark scores from previous studies.
Researchers have made significant advancements in nuclear medicine, improving treatment outcomes for prostate cancer, detecting cancer recurrence, and predicting treatment outcomes. Studies have shown that combining imaging methods, such as PET/CT and MRI, can improve detection of prostate cancer, while diagnostic scans may predict tum...
A study by National Institutes for Quantum Science and Technology researchers found that faster buildup of abnormal tau protein in the brain is linked to faster symptom worsening in progressive supranuclear palsy, a rare neurodegenerative disease. The discovery could help researchers objectively measure disease progression and accelera...
Researchers evaluated PET imaging with radiolabeled trastuzumab deruxtecan and targeted alpha therapy against HER2-positive cancer cells, revealing promising results in tracking therapy accumulation and suppressing tumor growth. PET imaging also linked metabolic patterns to pancreatic tumor outcomes and identified potential distant met...
A new PET imaging approach using carbonic anhydrase IX (CAIX) detected 97.9% of lesions in clear cell renal cell carcinoma (ccRCC), outperforming ¹⁸F-FDG PET/CT. The approach improved patient-level diagnostic accuracy in ccRCC, leading to changes in clinical management or disease stage in 30.9% of patients.
Researchers developed a next-generation PET/CT scanner that produces diagnostic-quality images in as little as one minute, surpassing the performance of conventional scanners. The study showed that even 90% shorter scans maintained high image quality, making it a game-changer for cancer diagnosis and treatment.
Recent studies published in The Journal of Nuclear Medicine investigate novel radiohybrid ligands for prostate cancer therapy, AI models predicting prostate cancer survival, and PET tracers for meningioma treatment. These advancements show promise for personalized medicine and improved patient outcomes.
Early assessment with 68Ga-HER2 PET/CT during neoadjuvant therapy can predict pathologic complete response in patients with HER2-positive breast cancer, with a 85% success rate for those with tumor uptake decrease of at least 61%. This finding has implications for timely consideration of alternative treatment strategies or surgery.
Researchers developed new imaging approaches and tracers to target prostate cancer, breast cancer, and other conditions. These methods showed promising results in improving detection and treatment outcomes.
Nuclear medicine is experiencing rapid growth with over 50 million procedures performed worldwide each year. EANM'26 will present the latest advances in nuclear medicine, molecular imaging, and radiopharmaceuticals, including theranostics and next-generation imaging technology.
A new study finds that PSMA PET/CT-guided targeted biopsy can detect clinically significant prostate cancer in 37% of men, compared to 21% with systematic biopsy alone. Combining the two approaches increases the detection rate to 41%.
Recent studies in The Journal of Nuclear Medicine have introduced new imaging techniques, including PET-based methods, to improve cancer diagnosis and treatment. Additionally, an open-source pipeline has been developed to automate tumor segmentation, and a new imaging approach has been shown to visualize therapeutic radionuclides.
Recent studies published in The Journal of Nuclear Medicine have investigated new treatments for liver fibrosis, thyroid cancer, and prostate cancer, including the use of PET tracers and radioactive iodine therapy. These studies have shown promising results, including improved imaging and biochemical responses, and increased radiation ...
New research in nuclear medicine advances detection and treatment of clear cell renal cell carcinoma with high accuracy, while SSTR antagonists show potential for imaging and treatment of neuroendocrine tumors. Alternative beta-emitting radionuclides are also being explored for targeted radiopharmaceutical therapy.
A new radiotracer, 18F-FDG PET/CT, has been shown to be highly effective in detecting rare and aggressive kidney cancer, renal medullary carcinoma (RMC). The tracer identified lesions in 98% of RMC patients and led to a change in treatment plan for 21% of patients with active disease, highlighting its potential to improve patient care.
Several new nuclear medicine approaches are being developed and evaluated for their potential to improve cancer imaging and treatment. Researchers have made significant progress in targeting specific markers and molecules in cancer cells, including CD163, CEACAM5, and DLL3. These advancements offer promising avenues for developing more...
A new multiplexing scheme enables deterministic light-sharing PET modules with improved power efficiency and data efficiency. The scheme reads out timestamps at the ASIC level, reducing power consumption without sacrificing coincidence time resolution.
A new study found that combining PET/MRI findings with EEG results and a structured presurgical evaluation improved the identification of seizure-causing brain tissue in pediatric epilepsy patients. 76 percent of patients who underwent surgery were free from seizures after two years of follow-up.
Researchers at USC developed an algorithmic tool to improve screening of patients for Alzheimer's clinical trials, reducing unnecessary PET scans by over half. The tool uses blood plasma biomarkers to identify patients at risk of Alzheimer's disease, enabling faster and more efficient recruitment for trials like AHEAD 3-45.
A new PET/MRI technique targeting fibroblast activation protein (FAP) overexpressed in endometriosis accurately maps the extent of the disease, enabling personalized management and improving patient outcomes. The approach was particularly effective in regions of the pelvis and abdomen that are typically difficult to image.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Researchers developed a dual-threshold approach for measuring tumor volume on PET/CT, showing higher total lesion volume associated with shorter overall survival and time to treatment failure. FAPI PET/CT improved detection of ovarian cancer spread, while CD8-targeted PET tracked immune response in lung cancer.
PSMA PET/CT detected recurrent prostate cancer after minimally invasive treatments and identified malignant peripheral nerve sheath tumors with high accuracy. Researchers also found varying access to PSMA-targeted theranostics between Brazil and Europe.
Research published in The Journal of Nuclear Medicine highlights the importance of intermediate amyloid PET uptake in Alzheimer's disease diagnosis and its association with cognitive decline. Additionally, studies show promising results for early SPECT/CT response prediction in PSMA-positive prostate cancer treatment, as well as potent...
New research articles published in The Journal of Nuclear Medicine explore intensified PSMA-targeted therapy for advanced prostate cancer, as well as novel approaches to targeted radiopharmaceutical therapy. Studies also investigate radiation doses from PSMA-targeted therapy and their relationship with treatment outcomes, while others ...
Researchers developed a multiprotein approach to predict advanced tau pathology among amyloid-positive individuals, outperforming p-tau217 alone. This study suggests a scalable alternative to tau PET staging for clinical or research settings.
A study published in Molecular Psychiatry found that about 65% of patients who developed psychosis after age 40 showed abnormal tau buildup, compared to 15% of healthy older controls. The findings suggest diverse tau-related brain changes may be involved in late-onset psychosis.
Researchers have developed a new biological treatment that targets inflammation-driven scarring after a heart attack, aiming to reduce the risk of heart failure. The treatment uses donated human bone marrow-produced exosomes to dampen inflammation and promote healing.
Researchers found that high brain metabolism is associated with longer overall survival, and it's an independent prognostic factor for overall survival. Brain metabolism measured by ¹⁸F-FDG PET/CT provides valuable insight into patient outcomes and may help identify patients most likely to benefit from early supportive care.
A new study published in The Journal of Nuclear Medicine has found that dual-energy SPECT may enable faster monitoring of PSMA therapy, reducing imaging time from 18 minutes to 9 minutes. Another study showed a prognostic model using PSMA PET can predict outcomes after therapy, including overall survival and PSA progression-free survival.
A new study found that PET/CT scans improved the diagnosis of fever of unknown origin (FUO) in nearly 75% of patients. The study identified predictive markers for a positive scan, including high C-reactive protein and short duration of prior antibiotic therapy.
Researchers have made significant breakthroughs in targeted radiation therapy for pancreatic cancer, PARP inhibitor treatment, and Alzheimer's disease detection. New PET-based scores may predict prostate cancer outcomes, while blood cell mutations are associated with side effects in advanced prostate cancer patients.
Researchers used PET imaging to find significantly lower muscarinic acetylcholine M1 receptor availability in schizophrenia patients compared to healthy individuals. This study provides the first in vivo evidence of widespread M1 receptor deficits in schizophrenia, supporting the development of muscarinic-based therapies.
A meta-analysis of individual participant data found that amyloid PET quantitation using centiloids can accurately diagnose Alzheimer's disease. The study suggests that scans in the 11-26 Centiloid range require caution, and a positivity cutoff of around 18 Centiloids is recommended.
Recent studies published in The Journal of Nuclear Medicine have shown that combining multiparametric MRI with PET improves the detection of clinically significant prostate cancer. Additionally, PSMA PET/CT-guided biopsies have been found to detect more significant cancers than standard biopsies.
A second PSMA PET scan changed treatment plans for nearly half of patients whose first scan was negative, detecting evidence of disease in 56% of cases. The study found that repeat imaging was most likely to detect disease in patients with higher PSA levels and a PSA doubling time of less than twelve months.
The Journal of Nuclear Medicine (JNM) has increased its impact factor from 9.1 to 9.6, ranking eighth overall among medical imaging journals. The journal saw a nearly 10% increase in citations and improved performance in various categories.
Researchers evaluated two somatostatin receptor PET tracers for breast cancer treatment, found SSTR-positive tumors in many estrogen receptor-positive cases. A new PET tracer showed promise for detecting Staph infections, while an interim PET scan may help track response to PSMA therapy in advanced prostate cancer.
Mary Beth Farrell has been honored with the 2026 SNMMI-TS Lifetime Achievement Award for her decades-long dedication to elevating the nuclear medicine profession. Her leadership in accreditation, research, and education has shaped national standards and driven quality improvement initiatives that continue to impact patient care.
A novel FAP-targeted radiopharmaceutical therapy approach has shown safety and effectiveness in treating various types of cancer, including breast, colorectal, gastric, and ovarian cancers. The treatment achieved objective responses in approximately two-thirds of patients and disease control in over 80%.
Research on targeted radioactive gold nanoparticles shows promise against aggressive brain tumors. Ultra-high-resolution PET scanners provide detailed views of mouse brains. New imaging tracers target key drivers of prostate cancer growth.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has announced the recipients of five Drs. Jane & Abass Alavi Mars Shot Research Awards, supporting studies on inflammatory bowel disease, artery inflammation, and other conditions.
FireANTs, an open-source algorithm, combines AI optimization and geometry to quickly match complex medical images. The new method can accomplish what took weeks in minutes, detecting subtle changes that signal disease or cognitive decline, making it practical for clinical practice.
The Journal of Nuclear Medicine has published several groundbreaking studies on targeted radiotherapy approaches for various types of cancer. Researchers have successfully identified tumors using fibroblast activation protein (FAP)-targeting compounds and explored the potential of PET/MRI scans in detecting endometriosis and recurrent ...
Gary Ulaner, a renowned nuclear medicine expert, has been elected president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He aims to advance SNMMI's Mars Shot initiative, expand educational activities for professionals, and increase funding for training new radiochemistry and physics specialists.
Researchers have identified RET as a biomarker for neuroendocrine prostate cancer and developed a theranostic pair for PET imaging and radioligand therapy. The approach demonstrates high uptake in tumors and shows promise for treatment, offering an alternative to current PSMA-based imaging.
Heather Jacene, MD, has been named president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), with a focus on strengthening the organization and advancing nuclear medicine. She plans to create new opportunities for members to participate actively in SNMMI and conduct multidisciplinary collaborations.
A new PET imaging approach measures synaptic density in the spinal cord, allowing physicians to monitor disease progression and evaluate treatment effectiveness. This technique detects widespread reductions in synaptic connections across the brain and spinal cord in patients with multiple sclerosis.
Jason Lewis, PhD, FSNMMI, has been elected as SNMMI's vice president-elect. He aims to strengthen education, scientific exchange, and outreach efforts to integrate basic scientists into SNMMI programs. Lewis holds various academic and research positions.
A new end-to-end PET imaging approach for osteosarcoma distinguishes tumor tissue from normal tissue and assesses surgical margins in real-time. The platform enables precise tumor resection, reducing the risk of local recurrence and preserving maximum limb function.
A novel PET imaging framework reveals bariatric surgery induces coordinated changes in metabolic function across organs, including fat, liver, pancreas, muscle, and immune-endocrine organs. These findings support the use of whole-body PET/CT as a tool to map organ-level metabolic health.
A new PET radiotracer, 18F-GP1 PET/CT, accurately detects deep vein thrombosis in the legs and reveals lung clot migration. The approach may support faster diagnosis and improve patient care by detecting disease early.
A newly developed portable point-of-care PET technology provides high-quality results for guiding biopsies, tumor ablations, and other interventional procedures. The bedside device offers real-time visual feedback, making it a cost-effective approach for hospitals to perform procedures in constrained clinical environments.
A new PET radiotracer can effectively image overactive adrenal glands, allowing for a non-invasive approach to diagnose primary aldosteronism. This could enable physicians to tailor treatment plans for patients with this condition.
A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC). The tracer successfully identified additional metastatic lesions missed by standard imaging while reducing abdominal background noise.
Dr. Martin G. Pomper has been awarded the 2026 Benedict Cassen Prize for his outstanding contributions to nuclear medicine, particularly in the development of PSMA-targeted agents. His work has led to significant advances in cancer diagnosis and treatment, including the creation of commercial PSMA-targeted PET agents.